Ana L M Batista de Carvalho
Overview
Explore the profile of Ana L M Batista de Carvalho including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
135
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Carvalho L, Cinque G, Batista de Carvalho A, Marques J, Frogley M, Vondracek H, et al.
Sci Rep
. 2024 Jul;
14(1):17166.
PMID: 39060284
The cellular response to cisplatin was assessed in human osteosarcoma cells, using synchrotron-based (SR) Fourier Transform InfraRed nanospectroscopy (nano-FTIR) at the MIRIAM beamline B22 of Diamond Light Source (UK). This...
2.
Laginha R, Silva J, Cinque G, de Carvalho L, Batista de Carvalho A
Spectrochim Acta A Mol Biomol Spectrosc
. 2024 May;
317:124389.
PMID: 38710137
Over the years, osteosarcoma therapy has had a significative improvement with the use of a multidrug regime strategy, increasing the survival rates from less than 20 % to circa 70 ...
3.
Carneiro T, Batista de Carvalho A, Vojtek M, Laginha R, Marques M, Diniz C, et al.
J Med Chem
. 2024 Apr;
67(8):6839-6853.
PMID: 38590144
Cisplatin (cDDP) resistance is a matter of concern in triple-negative breast cancer therapeutics. We measured the metabolic response of cDDP-sensitive (S) and -resistant (R) MDA-MB-231 cells to PdSpermine(Spm) (a possible...
4.
Felix M, Tavares M, Santos I, Batista de Carvalho A, de Carvalho L, Marques M
Molecules
. 2024 Mar;
29(5).
PMID: 38474435
Cervical cancer was considered the fourth most common cancer worldwide in 2020. In order to reduce mortality, an early diagnosis of the tumor is required. Currently, this type of cancer...
5.
Bispo D, Correia M, Carneiro T, Martins A, Reis A, Batista de Carvalho A, et al.
Int J Mol Sci
. 2023 Dec;
24(24).
PMID: 38139388
This work investigated the mechanisms of action of conventional drugs, cisplatin and oxaliplatin, and the potentially less deleterious drug PdSpermine (Spm) and its Pt(II) analog, against osteosarcoma MG-63 cells, using...
6.
Pinto S, Ferreira A, Teixeira D, Nunes S, Batista de Carvalho A, Almeida J, et al.
Chemistry
. 2023 Aug;
29(53):e202301442.
PMID: 37606898
A new fluorinated manganese porphyrin, (Mn-TPP-p-CF ) is reported capable of providing, based on the Mn(III)/Mn(II) equilibrium, dual H relaxivity and F NMR response to redox changes. The physical-chemical characterization...
7.
Vojtek M, Martins C, Ramos R, Duarte S, Ferreira I, Batista de Carvalho A, et al.
Pharmaceutics
. 2023 Apr;
15(4).
PMID: 37111690
Triple-negative breast cancer (TNBC) is one of the most aggressive forms of breast cancer and constitutes 10-20% of all breast cancer cases. Even though platinum-based drugs such as cisplatin and...
8.
Silva J, Marques J, Santos I, Batista de Carvalho A, Martins C, Laginha R, et al.
Molecules
. 2023 Feb;
28(4).
PMID: 36838683
A dinuclear Pt(II) complex with putrescine as bridging polyamine ligand ([PtPut(NH)]Cl) was synthesized and assessed as to its potential anticancer activity against a human non-small cell lung cancer line (A549),...
9.
Laginha R, Martins C, Brandao A, Marques J, Marques M, de Carvalho L, et al.
Int J Mol Sci
. 2023 Feb;
24(3).
PMID: 36768221
Regarding the development of new antineoplastic agents, with a view to assess the selective antitumoral potential which aims at causing irreversible damage to cancer cells while preserving the integrity of...
10.
Carneiro T, Vojtek M, Goncalves-Monteiro S, Batista de Carvalho A, Marques M, Diniz C, et al.
Int J Mol Sci
. 2022 Nov;
23(22).
PMID: 36430252
Cisplatin (cDDP)-based chemotherapy is often limited by severe deleterious effects (nephrotoxicity, hepatotoxicity and neurotoxicity). The polynuclear palladium(II) compound PdSpermine (PdSpm) has emerged as a potential alternative drug, with favorable pharmacokinetic/pharmacodynamic...